Stop TB Partnership

Aeras and IDRI Sign Agreement to Jointly Develop Novel Tuberculosis Vaccine

9 May 2012 - Rockville and Seattle, USA - Aeras and the Infectious Disease Research Institute (IDRI) have agreed to conduct joint development activities on a new tuberculosis (TB) vaccine candidate.

IDRI’s vaccine candidate, ID93/GLA-SE, is composed of an recombinant fusion-protein antigen plus IDRI’s proprietary adjuvant, GLA. The adjuvant has been tested in humans but has not been used in any other TB vaccine currently in clinical development. The vaccine candidate targets both active TB and latent TB.

"Tuberculosis is one of the most widespread, persistent and deadly global health problems," said Dr Steven Reed, IDRI founder and Chief Scientific Officer. "Given Aeras’ focus and breadth of experience in supporting the clinical development of tuberculosis vaccines, we believe this collaboration will speed the development of this promising new vaccine."